摘要
目的 研究Ki 67在乳腺癌中的表达与临床病理特征的关系.方法 应用免疫组织化学方法检测120例女性乳腺癌患者中Ki-67、ER、PR、C-erbB-2的表达,分析Ki-67与ER、PR 、C-erbB-2、肿瘤大小、淋巴结转移情况、年龄、月经状况、病理组织学分级等临床病理特征的关系.结果 120例患者乳腺癌组织中Ki-67表达（-）6例（5％）；Ki-67表达（＋）36例（30％）；Ki-67表达（＋＋）31例（25.83％）；Ki-67表达（＋＋＋）47例（39.17％）.Ki-67表达与乳腺癌组织中C-erbB-2表达、肿瘤大小、淋巴结转移情况、患者年龄、月经状况之间差异无统计学意义（P＞0.05）；与ER、PR受体表达、肿瘤组织学分级相关（P＜0.05）.结论 Ki-67不能作为评估乳腺癌预后和指导临床治疗的重要指标.
Objective To investigate the expressing of Ki-67 in breast cancer tissues and explore the relationship between it and the clinic pathology characteristics.Methods Immunohistochemical SP was used to investigate Ki-67,ER,PR,C-erbB-2 expression in 120 cases of female breast cancer.Analysis the relatiouship between Ki67 and ER,PR,C-erbB-2,tunor size,lymph node metastasis,patients age,menstruation state and clinic pathology characteristics.Results Six cases＇ Ki-67 expression in 120 eases of female patients with breast cancer tissue were （-） （5％）,36 cases＇ ki-67 expression were （＋） （30％）,31 cases Ki-67 Expression were （＋ ＋）（25.83％）,37 cases＇ Ki-67 expression were （＋ ＋ ＋） 39.17％.The expression of ki-67 did not correlate with the expression of C-crbB-2,tumor size,lymph node metastasis,patients age and menstruation state（P ＞0.05）.The expression of ki-67 correlate with hormone receptor status and histology pathology classification.Conclusion Ki-67 cannot serve as an important index of evaluating prognosis of breast cancer and to guide clinical treatment.
出处
《国际外科学杂志》
2013年第9期604-607,F0003,共5页
International Journal of Surgery
